CN109125525A - Composition of prevention and cure of cardiovascular disease and its preparation method and application - Google Patents

Composition of prevention and cure of cardiovascular disease and its preparation method and application Download PDF

Info

Publication number
CN109125525A
CN109125525A CN201710458452.8A CN201710458452A CN109125525A CN 109125525 A CN109125525 A CN 109125525A CN 201710458452 A CN201710458452 A CN 201710458452A CN 109125525 A CN109125525 A CN 109125525A
Authority
CN
China
Prior art keywords
cardiovascular disease
cure
prevention
composition
lactobacillus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201710458452.8A
Other languages
Chinese (zh)
Other versions
CN109125525B (en
Inventor
司朝利
廖振林
黄琪评
郑志民
秦伟灵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Kangyouyuan Biotechnology Co ltd
Original Assignee
Guangzhou Kangyouyuan Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Kangyouyuan Biotechnology Co ltd filed Critical Guangzhou Kangyouyuan Biotechnology Co ltd
Priority to CN201710458452.8A priority Critical patent/CN109125525B/en
Publication of CN109125525A publication Critical patent/CN109125525A/en
Application granted granted Critical
Publication of CN109125525B publication Critical patent/CN109125525B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/169—Plantarum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/41—Pediococcus
    • A23V2400/413—Acidilactici
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/41—Pediococcus
    • A23V2400/427—Pentosaceus

Abstract

The present invention relates to compositions of a kind of prevention and cure of cardiovascular disease and its preparation method and application.The composition by weight percentage, including following components: cyanidin extract 3-20%, lactic acid bacteria 3-20%, oligoisomaltose 5-22%, konjaku 5-22%, inulin 8-23%, fructus hippophae 1-10%, vitamin C 1-10%, vitamin E 1-6%, maltodextrin 8-25%；The lactic acid bacteria is lactobacillus reuteri, Lactobacillus rhamnosus, lactobacillus plantarum, Pediococcus acidilactici and the combination of Pediococcus pentosaceus.Composition of the invention has anti-oxidant, defaecation, adjusts a variety of effects such as intestinal microecology, reducing blood lipid, softening blood vessel, atherosclerosis, can effectively prevent cardiovascular disease, provide a new treatment method for cardiovascular patient.

Description

Composition of prevention and cure of cardiovascular disease and its preparation method and application
Technical field
The present invention relates to drug or food technology fields, a kind of composition more particularly to prevention and cure of cardiovascular disease and its Preparation method and application.
Background technique
It is counted according to clinical data, cardiovascular disease occupies 40% or more of people's disease death composition, is China resident's The first cause of the death.Cardiovascular disease burden increasingly aggravates, it has also become great public health problem, prevention and cure of cardiovascular disease quarter are not allowed It is slow.
Treatment for cardiovascular disease relies primarily on antiarrhythmic drug and is controlled, and takes anti-arrhythmia for a long time Although drug can obtain different degrees of control to the state of an illness, its side reaction harm is consequently increased.
Intestinal microflora, which contains beneficial bacterium, neutral bacterium and harmful bacteria, these types of microorganism, in human body maintains phase Pair balance.With the continuous research to enteric microorganism, find enteric microorganism it is unbalance can by promote cholesterol accumulation, Oxidative stress, inflammatory factor release promote atherosclerosis generation, and the probiotics in enteron aisle can reduce cholesterolemia, The expression for inhibiting inflammatory factor has certain protective effect to angiocarpy.
Summary of the invention
Based on this, the present invention provides a kind of compositions that can effectively prevent cardiovascular disease.
Specific technical solution is as follows:
A kind of composition of prevention and cure of cardiovascular disease, by weight percentage, including following components:
The lactic acid bacteria is lactobacillus reuteri, Lactobacillus rhamnosus, lactobacillus plantarum, Pediococcus acidilactici and pentose piece ball The combination of bacterium.
The cyanidin extract is the cyanidin extract extracted from fruit, these fruits can be black fruit fructus lycii, Mulberry fruit, blueberry, grape, blackcurrant etc..The fructus hippophae is fructus hippophae freeze-dried powder, and the konjaku is konjaku powder, the cream Sour bacterium is the freeze-dried powder of lactic acid bacteria.The sweetener includes steviol glycoside freeze-dried powder.
In wherein some embodiments, the composition of the prevention and cure of cardiovascular disease, by weight percentage, including it is following Component:
In wherein some embodiments, the composition of the prevention and cure of cardiovascular disease, by weight percentage, including it is following Component:
In wherein some embodiments, the composition of the prevention and cure of cardiovascular disease, by weight percentage, including it is following Component:
In wherein some embodiments, the composition of the prevention and cure of cardiovascular disease, by weight percentage, further include with Lower component:
Cornstarch 12-20%
Sweetener 0.25-0.5%.
In wherein some embodiments, the lactobacillus reuteri is the Luo Yishi cream bar that deposit number is GDMCC60148 Bacterium (Lactobacillus reuteri, GDMCC60148), the Lactobacillus rhamnosus are that deposit number is GDMCC60147 Lactobacillus rhamnosus (Lactobacillus rhamnosus, GDMCC60147), the lactobacillus plantarum is that deposit number is The lactobacillus plantarum (Lactobacillus plantarum, GDMCC60151) of GDMCC60151, the Pediococcus acidilactici are to protect The Pediococcus acidilactici (Pediococcus acidilactici, GDMCC60150) that hiding number is GDMCC60150, the pentose Piece coccus is the Pediococcus pentosaceus (Pediococcus pentosaceus, GDMCC60149) that deposit number is GDMCC60149.
In wherein some embodiments, the lactic acid bacteria is consisted of the following components in percentage by weight:
In wherein some embodiments, the lactic acid bacteria is consisted of the following components in percentage by weight:
In wherein some embodiments, the lactic acid bacteria is consisted of the following components in percentage by weight:
In wherein some embodiments, the preparation method of the cyanidin extract the following steps are included:
Raw material and extractant are added in extraction vessel, ultrasonic extraction 1.5-2.5 under conditions of temperature is 55-65 DEG C Hour, filtering, filtrate centrifugation will be freeze-dried again after the concentration of gained supernatant to get the cyanidin extract；
The raw material are black fruit fructus lycii, Mulberry fruit, blueberry, grape, blackcurrant；
The extractant is the acidic ethanol extractant configured as follows: being 0.09- by mass fraction The ethanol water that 0.11% aqueous hydrochloric acid solution is 90-98% with volume fraction is that 38-42:58-62 is mixed by volume It closes；
The proportion of the raw material and extractant is 1g:35-45ml.
In wherein some embodiments, the viable count of the lactic acid bacteria is 109cfu/g-1011cfu/g。
In wherein some embodiments, the viable count of the lactic acid bacteria is 1010cfu/g。
The present invention also provides the preparation methods of the composition of above-mentioned prevention and cure of cardiovascular disease.
Specific technical solution is as follows:
A kind of preparation method of the composition of above-mentioned prevention and cure of cardiovascular disease, comprising the following steps: extract anthocyanidin Object, oligoisomaltose, konjaku powder, inulin, fructus hippophae freeze-dried powder, vitamin C, vitamin E, cornstarch, maltodextrin With sweetener mixing, dry, then add the freeze-dried powder of lactic acid bacteria, be uniformly mixed to get.
The present invention also provides the applications of the composition of above-mentioned prevention and cure of cardiovascular disease.
Specific technical solution is as follows:
Application of the combinations of the above object in the drug or food for preparing prevention and cure of cardiovascular disease.Above-mentioned prevention and treatment is cardiovascular The composition of disease has effects that reducing blood lipid, reduces cholesterol, softening blood vessel, mitigates symptoms of atherosclerosis, final to rise To the effect of prevention cardiovascular disease and mitigation disease symptoms.
The present invention also provides a kind of drug of prevention and cure of cardiovascular disease or food.
Specific technical solution is as follows:
A kind of drug or food of prevention and cure of cardiovascular disease contain above-mentioned prevention and treatment angiocarpy disease in the drug or food The composition of disease.
In the composition of prevention and cure of cardiovascular disease of the invention, the major function of each component is as follows:
Anthocyanidin has a variety of action and efficacies, it has very strong antioxidation, can remove the intracorporal super oxygen of people certainly By base and hydroxy radical；It is able to suppress the Main Factors for causing atherosclerosis --- the oxidation of low-density albumen and blood platelet Agglutination, to reduce the generation of heart disease and stroke；It is able to maintain the flexibility of orthocytosis, enhancing artery, vein and hair Thin blood vessel elasticity enables erythrocyte easily by tiny capillary, to enhance the blood circulation of whole body, is body The organ and system of various pieces bring direct benefit.But in human body, anthocyanidin must be in the effect of enteric microorganism Lower generation bioconversion is metabolized to anti-oxidant, antibacterial, softening blood vessel the effect of protocatechuic acid competence exertion.
Lactobacillus reuteri inhibits TNF-α to inspire scorching gene, synthetic fatty acid SREBP-1c gene, activating metabolism fat Sour PPAR γ gene, therefore have the function of to promote fatty acid and cholesterol metabolic, it can reduce the cholesterol level in blood plasma.
Lactobacillus rhamnosus can reduce cholesterol, adjust blood lipid, can increase the expression of IL-10 specific complex receptor, And macrophage inflammatory protein (MIP) -2, TNF-α level are reduced, to angiocarpy, there are protective effects.
Pediococcus acidilactici can enhance host to the nonspecific resistance of microbial pathogens, accelerate cause of disease in enteron aisle The removing of body.
Lactobacillus plantarum, it is strong to the biotransformation capacity of anthocyanidin, it generates beneficial to cardiovascular molecular substance.
Pediococcus pentosaceus hinders the synthesis of cholesterol, reduces cholesterol level in blood plasma；Anthocyanidin can be carried out simultaneously Bioconversion generates protocatechuic acid.
Maltodextrin, oligoisomaltose can provide prebiotics for probiotics, promote field planting of the probiotics in enteron aisle.
Konjaku plays the role of reducing blood lipid and hypoglycemic and good defecating feces excretion.
Inulin can effectively reduce serum total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C), improve high density Lipoprotein/low-density lipoprotein (HDL/LDL) ratio improves status of blood lipid, while making proliferation of probiotics as prebiotics, and mention For smooth mouthfeel and balance mellow and full flavor.
Fructus hippophae contains multivitamin, fatty acid, microelement, sub- oily element, Hippophate flavone, superoxides isoreactivity The various amino acid of substance and needed by human body can reduce cholesterol, cure angina pectoris etc., and there are also prevent and treat coronary atherosclerosis The cardiopathic effect of property.
Vitamin C, antioxidant, threat of the protection body from free radical.
Vitamin E, antioxidant can prevent damage of the free radical to vascular wall, thus prevention of arterial atherosis, coronary disease Disease.
Above-mentioned each component influences each other, and mutually promotes, and complements each other, and plays reducing blood lipid jointly, reduces cholesterol, softening blood Pipe, the effect for mitigating symptoms of atherosclerosis, have the function of synergy for prevention and cure of cardiovascular disease.
Therefore, the composition of prevention and cure of cardiovascular disease and its preparation method and application of the invention has the following advantages that and has Beneficial effect:
The present invention is combined using specific functional raw material and specific probiotics, and has been especially added with prebiotics, right Field planting of the probiotics in enteron aisle, proliferation are very helpful, and obtained composition has anti-oxidant, defaecation, adjusts enteron aisle A variety of effects such as Tiny ecosystem, reducing blood lipid, softening blood vessel, atherosclerosis, can effectively prevent cardiovascular disease, be the heart Vascular disease provides a new treatment method.
In composition of the invention, lactic acid bacteria group becomes specific functional bacterial strain, the resistance to bile acid ability of stomach juice-resistant By force, it can be colonized in enteron aisle by stomach.
It is wide that functional natural material and probiotics employed in composition of the invention carry out source range, highly-safe.
Detailed description of the invention
Fig. 1 is the cholesterol residual volume that lactic acid bacteria and cholesterol co-culture 24 hours.
Specific embodiment
Below in conjunction with specific embodiment to the composition of prevention and cure of cardiovascular disease and its preparation method and application of the invention Do further details of elaboration.
Lactobacillus reuteri of the invention, Lactobacillus rhamnosus, lactobacillus plantarum, Pediococcus acidilactici, Pediococcus pentosaceus are all It is preserved in Guangdong Province's Culture Collection (DGMCC) on March 13rd, 2017, deposit number is respectively GDMCC60148, GDMCC60147, GDMCC60151, GDMCC60150, GDMCC60149, storage life are 30 years, preservation Location is the compound the 59th of Xianlie Middle Road, Guangzhou City 100 5 building, building.
Lactobacillus reuteri (Lactobacillus reuteri, GDMCC60148): healthy human body excrement is derived from；
Lactobacillus rhamnosus (Lactobacillus rhamnosus, GDMCC60147): healthy human body excrement is derived from；
Lactobacillus plantarum (Lactobacillus plantarum, GDMCC60151): Quanzhou fermented soya bean are derived from；
Pediococcus acidilactici (Pediococcus acidilactici, GDMCC60150): from raising clearweed fermented soya beans, salted or other wise；
With Pediococcus pentosaceus (Pediococcus pentosaceus, GDMCC60149): deriving from Huaiji dishes made from scrambled eggs；
The above lactic acid bacteria is voluntarily screening and culturing, and the specific method is as follows:
A small amount of above-mentioned source material is taken respectively, is added in 10mL physiological saline, after shaking up, 1mL supernatant is taken successively to dilute, Take 100uL105、106、107Dilution is crossed on MRS plating medium separates strain.
Plate is cultivated at 37 DEG C observes bacterium colony after for 24 hours~48h, and picking milky, white, faint yellow, there is molten calcium circle, Produce sour (having tart flavour) has the bacterium colony of lactic acid bacteria feature in the MRS meat soup of 1mL, cultivates at 37 DEG C for 24 hours, flat in MRS later It crosses on plate, to obtain pure single colonie.It repeats the above steps 2 times or more, until obtaining pure bacterial strain.And it is protected with glycerol It deposits.Fermentation expands culture, freeze-drying obtains the freeze-dried powder of the above lactic acid bacteria.
Embodiment 1
The composition of the prevention and cure of cardiovascular disease of the present embodiment is prepared: cyanine by the raw material of following weight percent Extract 10%, lactic acid bacteria 10%, oligoisomaltose 12%, konjaku 13%, inulin 13%, fructus hippophae 4.5%, vitamin C 5%, vitamin E 2%, cornstarch 15%, maltodextrin 15%, steviol glycoside 0.5%.
Wherein, cyanidin extract is the cyanidin extract extracted from black fruit fructus lycii, and specific extracting method is as follows:
Process flow: weigh → plus extractant → ultrasonic extraction → filtering → centrifugation → concentrated by rotary evaporation → freeze-drying.Match Extractant processed are as follows: HC1 aqueous solution that mass fraction is 0.1% and the ethanol water that volume fraction is 95% in parts by weight 40: 60 (V/V) mixing, obtains acidic ethanol extractant.
It is 1:40 according to the material ratio of raw material and extractant, weighs black fruit fructus lycii powder 25g, pour into the beaker of 2L, then plus Enter acidic ethanol extractant 1L, during which ultrasonic wave extraction 120min under the conditions of 60 DEG C of waters bath with thermostatic control is suitably stirred.Extraction terminates Afterwards with 4 layers of clean filtered through gauze, insoluble matter in de-black fruit wolfberry fruit syrup, after collecting filtrate, 3000rpm room temperature is centrifuged 10 points Clock collects supernatant and obtains clear black fruit fructus lycii anthocyanidin crude extract, under the conditions of 60 DEG C of vacuum rotary evaporator, -1.0Mpa, rotation It boils off to remove ethyl alcohol and be concentrated into 250mL and obtains black fruit fructus lycii anthocyanidin crude extract, freeze-drying is to get anthocyanidin extraction Object, 4 DEG C keep in dark place at low temperature, spare.
Steviol glycoside is steviol glycoside freeze-dried powder, and konjaku is konjaku powder, and fructus hippophae is fructus hippophae freeze-dried powder, and lactic acid bacteria is Lactobacillus reuteri (Lactobacillus reuteri, GDMCC60148), Lactobacillus rhamnosus (Lactobacillus Rhamnosus, GDMCC60147), lactobacillus plantarum (Lactobacillus plantarum, GDMCC60151), lactic acid sheet ball Bacterium (Pediococcus acidilactici, GDMCC60150) and Pediococcus pentosaceus (Pediococcus pentosaceus, GDMCC60149 freeze-dried mixed powder), viable count 1010cfu/g；The weight percent of each bacterium in the lactic acid bacteria freeze drying powder Are as follows:
The composition of the prevention and cure of cardiovascular disease of the present embodiment, preparation method are as follows: by cyanidin extract, oligomeric different Maltose, konjaku powder, inulin, fructus hippophae freeze-dried powder, vitamin C, vitamin E, cornstarch, maltodextrin and sweetener are mixed Close, be dry, then adding the freeze-dried powder of lactic acid bacteria, be uniformly mixed to get.
Embodiment 2
The composition of the prevention and cure of cardiovascular disease of the present embodiment is prepared: cyanine by the raw material of following weight percent Extract 8%, lactic acid bacteria 8%, oligoisomaltose 13%, konjaku 13%, inulin 13%, fructus hippophae 5%, vitamin C 5%, vitamin E 2.5%, cornstarch 17%, maltodextrin 15%, steviol glycoside 0.5%.
Wherein, cyanidin extract is the cyanidin extract extracted from black fruit fructus lycii, and extracting method is the same as embodiment 1. Steviol glycoside is steviol glycoside freeze-dried powder, and konjaku is konjaku powder, and fructus hippophae is fructus hippophae freeze-dried powder, and lactic acid bacteria is Luo Yishi cream Bacillus (Lactobacillus reuteri, GDMCC60148), Lactobacillus rhamnosus (Lactobacillus rhamnosus, GDMCC60147), lactobacillus plantarum (Lactobacillus plantarum, GDMCC60151), Pediococcus acidilactici (Pediococcus acidilactici, GDMCC60150) and Pediococcus pentosaceus (Pediococcus pentosaceus, GDMCC60149 freeze-dried mixed powder), viable count 1010cfu/g；The weight percent of each bacterium in the lactic acid bacteria freeze drying powder Are as follows:
The preparation method is the same as that of Example 1.
Embodiment 3
The composition of the prevention and cure of cardiovascular disease of the present embodiment is prepared: cyanine by the raw material of following weight percent Extract 5%, lactic acid bacteria 15%, oligoisomaltose 8%, konjaku 17%, inulin 18%, fructus hippophae 7%, vitamin C 2.5%, vitamin E 4%, cornstarch 20%, maltodextrin 10%, steviol glycoside 0.5%.
Wherein, cyanidin extract is the cyanidin extract extracted from black fruit fructus lycii, and extracting method is the same as embodiment 1. Steviol glycoside is steviol glycoside freeze-dried powder, and konjaku is konjaku powder, and fructus hippophae is fructus hippophae freeze-dried powder, and lactic acid bacteria is Luo Yishi cream Bacillus (Lactobacillus reuteri, GDMCC60148), Lactobacillus rhamnosus (Lactobacillus rhamnosus, GDMCC60147), lactobacillus plantarum (Lactobacillus plantarum, GDMCC60151), Pediococcus acidilactici (Pediococcus acidilactici, GDMCC60150) and Pediococcus pentosaceus (Pediococcus pentosaceus, GDMCC60149 freeze-dried mixed powder), viable count 1010cfu/g；The weight percent of each bacterium in the lactic acid bacteria freeze drying powder Are as follows:
The preparation method is the same as that of Example 1.
Embodiment 4
The composition of the prevention and cure of cardiovascular disease of the present embodiment is prepared: cyanine by the raw material of following weight percent Extract 15%, lactic acid bacteria 5%, oligoisomaltose 15%, konjaku 8%, inulin 10%, fructus hippophae 2.7%, vitamin C 8%, vitamin E 1%, cornstarch 15%, maltodextrin 20%, steviol glycoside 0.5%.
Wherein, cyanidin extract is to be extracted from black fruit fructus lycii by the anthocyanidin that the hot microwave leaching technology of ultrasonic wave-extracts Object, extracting method is the same as embodiment 1.Steviol glycoside is steviol glycoside freeze-dried powder, and konjaku is konjaku powder, and fructus hippophae is sea-buckthorn jelly Dry powder, lactic acid bacteria are lactobacillus reuteri (Lactobacillus reuteri, GDMCC60148), Lactobacillus rhamnosus (Lactobacillus rhamnosus, GDMCC60147), lactobacillus plantarum (Lactobacillus plantarum, GDMCC60151), Pediococcus acidilactici (Pediococcus acidilactici, GDMCC60150) and Pediococcus pentosaceus The freeze-dried mixed powder of (Pediococcus pentosaceus, GDMCC60149), viable count 1010cfu/g；The lactic acid bacteria The weight percent of each bacterium in freeze-dried powder are as follows:
The preparation method is the same as that of Example 1.
5 norcholesterol experiment in vitro of embodiment
Experimental method:
The water-soluble cholesterol of 100 μ g/ml is added in MRS culture medium, and the lactic acid bacteria freeze drying powder in embodiment 1 is added, Viable bacteria inoculum concentration is 1%, is cultivated 24 hours at 37 DEG C.In incubation, using syringe different periods (0h, 6h, 12h, Culture solution is extracted for 24 hours), uses spectrophotometer to measure its absorbance value at 620nm after centrifugal treating.
Experimental result is as shown in Figure 1, lactic acid bacteria is by assimilation cholesterol, and cholesterol reduces by 19% when cultivating 6h, training Cholesterol reduces by 40% when supporting 12h, and cultivating cholesterol when for 24 hours reduces by 55%.
6 zoopery of embodiment
Experimental animal: ApoE-/-Mouse.
Atherosclerosis modeling method: with high lipid food, (15.0% fat of addition, 1.25% gallbladder are solid in normal diet Alcohol, 0.5% cholic acid, 0.2% methylthiouracil) feed ApoE-/-Mouse induces ApoE-/-Mouse is dynamic for atherosclerosis Object model.Normal diet are as follows: NRC standard AIN93 feed.
Experiment flow:
Experimental animal is randomly divided into 6 groups, every group 10, is fed with the following methods respectively (table 1), after feeding 4 weeks, The serum of experimental animal is acquired, the biochemical indicator in serum: serum total cholesterol (TC), triglycerides (TG), low-density is detected Lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), malonaldehyde (MDA).
The difference of composition 1 used in control group 1 and the composition of embodiment 1 is to extract without lactic acid bacteria and anthocyanidin Object.
The difference of composition 2 used in control group 2 and the composition of embodiment 1 is without lactic acid bacteria.
The difference of composition 3 used in control group 3 and the composition of embodiment 1 is without cyanidin extract.
Table 1: experimental group
Experimental result is as shown in table 2:
Table 2: every measurement index of different feeding mode animal
As can be seen from the above table, the mouse of the composition of 4 weeks embodiments 1 preparation, total cholesterol, glycerol in serum are fed The raising of three esters is all controlled effectively, and then can reduce the probability of cardiovascular disease generation.
It is found through experiments that, the composition of other embodiments preparation of the present invention all has similar effect.
Each technical characteristic of embodiment described above can be combined arbitrarily, for simplicity of description, not to above-mentioned reality It applies all possible combination of each technical characteristic in example to be all described, as long as however, the combination of these technical characteristics is not deposited In contradiction, all should be considered as described in this specification.
The embodiments described above only express several embodiments of the present invention, and the description thereof is more specific and detailed, but simultaneously It cannot therefore be construed as limiting the scope of the patent.It should be pointed out that coming for those of ordinary skill in the art It says, without departing from the inventive concept of the premise, various modifications and improvements can be made, these belong to protection of the invention Range.Therefore, the scope of protection of the patent of the invention shall be subject to the appended claims.

Claims (10)

1. a kind of composition of prevention and cure of cardiovascular disease, which is characterized in that by weight percentage, including following components:
The lactic acid bacteria is lactobacillus reuteri, Lactobacillus rhamnosus, lactobacillus plantarum, Pediococcus acidilactici and Pediococcus pentosaceus Combination.
2. the composition of prevention and cure of cardiovascular disease according to claim 1, which is characterized in that by weight percentage, packet Include following components:
3. the composition of prevention and cure of cardiovascular disease according to claim 1, which is characterized in that by weight percentage, also Including following components:
Cornstarch 12-20%
Sweetener 0.25-0.5%.
4. the composition of prevention and cure of cardiovascular disease according to claim 1-3, which is characterized in that the Luo Yishi Lactobacillus is the lactobacillus reuteri (Lactobacillus reuteri, GDMCC60148) that deposit number is GDMCC60148, The Lactobacillus rhamnosus be deposit number be GDMCC60147 Lactobacillus rhamnosus (Lactobacillus rhamnosus, GDMCC60147), the lactobacillus plantarum is the lactobacillus plantarum that deposit number is GDMCC60151 (Lactobacillusplantarum, GDMCC60151), the Pediococcus acidilactici are the creams that deposit number is GDMCC60150 Sour piece coccus (Pediococcus acidilactici, GDMCC60150), the Pediococcus pentosaceus is that deposit number is The Pediococcus pentosaceus (Pediococcuspentosaceus, GDMCC60149) of GDMCC60149.
5. the composition of prevention and cure of cardiovascular disease according to claim 1-3, which is characterized in that the lactic acid bacteria It consists of the following components in percentage by weight:
6. the composition of prevention and cure of cardiovascular disease according to claim 1-3, which is characterized in that the anthocyanidin The preparation method of extract the following steps are included:
Raw material and extractant are added in extraction vessel, ultrasonic extraction 1.5-2.5 is small under conditions of temperature is 55-65 DEG C When, filtering, filtrate centrifugation will be freeze-dried again after the concentration of gained supernatant to get the cyanidin extract；
The raw material are black fruit fructus lycii, Mulberry fruit, blueberry, grape, blackcurrant；
The extractant is the acidic ethanol extractant configured as follows: being 0.09-0.11% by mass fraction Aqueous hydrochloric acid solution is that 38-42:58-62 is mixed with the ethanol water that volume fraction is 90-98% by volume；
The proportion of the raw material and extractant is 1g:35-45ml.
7. the composition of prevention and cure of cardiovascular disease according to claim 1-3, which is characterized in that the lactic acid bacteria Viable count be 109cfu/g-1011cfu/g。
8. a kind of preparation method of the composition of the described in any item prevention and cure of cardiovascular disease of claim 1-7, which is characterized in that The following steps are included: by cyanidin extract, oligoisomaltose, konjaku powder, inulin, fructus hippophae freeze-dried powder, vitamin C, Vitamin E, cornstarch, maltodextrin and sweetener mixing, drying, then the freeze-dried powder of lactic acid bacteria is added, it is uniformly mixed, i.e., ?.
9. application of the described in any item compositions of claim 1-7 in the drug or food for preparing prevention and cure of cardiovascular disease.
10. the drug or food of a kind of prevention and cure of cardiovascular disease, which is characterized in that contain claim in the drug or food The composition of the described in any item prevention and cure of cardiovascular disease of 1-7.
CN201710458452.8A 2017-06-16 2017-06-16 Composition for preventing and treating cardiovascular diseases and preparation method and application thereof Active CN109125525B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710458452.8A CN109125525B (en) 2017-06-16 2017-06-16 Composition for preventing and treating cardiovascular diseases and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710458452.8A CN109125525B (en) 2017-06-16 2017-06-16 Composition for preventing and treating cardiovascular diseases and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN109125525A true CN109125525A (en) 2019-01-04
CN109125525B CN109125525B (en) 2021-06-15

Family

ID=64830697

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710458452.8A Active CN109125525B (en) 2017-06-16 2017-06-16 Composition for preventing and treating cardiovascular diseases and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN109125525B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109182225A (en) * 2018-10-30 2019-01-11 吉林省农业科学院 One plant of Pediococcus acidilactici and its application in antiatherosclerosis
CN111500520A (en) * 2020-06-02 2020-08-07 光明乳业股份有限公司 Method for culturing lactobacillus plantarum
CN113249249A (en) * 2021-04-29 2021-08-13 南昌大学 Lactobacillus plantarum ZDY04 with effect of relieving atherosclerosis
WO2023237688A1 (en) * 2022-06-10 2023-12-14 Dsm Ip Assets B.V. Combinations comprising vitamin c and lactobacillus rhamnosus
WO2023237684A1 (en) * 2022-06-10 2023-12-14 Dsm Ip Assets B.V. Combinations comprising vitamin c and lactobacillus rhamnosus
WO2023237689A1 (en) * 2022-06-10 2023-12-14 Dsm Ip Assets B.V. Combinations comprising vitamin c and lactobacillus rhamnosus
WO2023237686A1 (en) * 2022-06-10 2023-12-14 Dsm Ip Assets B.V. Combinations comprising vitamin c and lactobacillus rhamnosus

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101601812A (en) * 2008-06-11 2009-12-16 黄刚 A kind of nutrient that can strengthen human immunity and protecting heart and brain Autoscreen II enterocyte
CN104694409A (en) * 2013-12-06 2015-06-10 深圳华大基因科技有限公司 Lactobacillus plantarum and uses thereof
WO2015105437A1 (en) * 2014-01-13 2015-07-16 Ockerman Per-Arne Multi nutrient supplementation
CN105287649A (en) * 2015-11-23 2016-02-03 西安木本贞生物科技有限公司 Medical probiotics capsule
CN105725123A (en) * 2016-04-01 2016-07-06 邵素英 Blueberry composite powder high in anthocyanin content and preparing method thereof
CN105779343A (en) * 2016-03-28 2016-07-20 济南康多宝生物技术有限公司 Lactobacillus plantarum capable of effectively removing cholesterol and free radicals and application thereof
CN105852101A (en) * 2016-04-15 2016-08-17 劲膳美生物科技股份有限公司 Medical formula food for treating coronary heart disease
CN106243075A (en) * 2016-08-03 2016-12-21 安徽徽王农业有限公司 The separation method of vaccinium oxycoccus pigment
CN106389763A (en) * 2016-09-09 2017-02-15 成都六然医疗科技有限公司 Red complex probiotics composition for heart and cerebral vessels

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101601812A (en) * 2008-06-11 2009-12-16 黄刚 A kind of nutrient that can strengthen human immunity and protecting heart and brain Autoscreen II enterocyte
CN104694409A (en) * 2013-12-06 2015-06-10 深圳华大基因科技有限公司 Lactobacillus plantarum and uses thereof
WO2015105437A1 (en) * 2014-01-13 2015-07-16 Ockerman Per-Arne Multi nutrient supplementation
CN105287649A (en) * 2015-11-23 2016-02-03 西安木本贞生物科技有限公司 Medical probiotics capsule
CN105779343A (en) * 2016-03-28 2016-07-20 济南康多宝生物技术有限公司 Lactobacillus plantarum capable of effectively removing cholesterol and free radicals and application thereof
CN105725123A (en) * 2016-04-01 2016-07-06 邵素英 Blueberry composite powder high in anthocyanin content and preparing method thereof
CN105852101A (en) * 2016-04-15 2016-08-17 劲膳美生物科技股份有限公司 Medical formula food for treating coronary heart disease
CN106243075A (en) * 2016-08-03 2016-12-21 安徽徽王农业有限公司 The separation method of vaccinium oxycoccus pigment
CN106389763A (en) * 2016-09-09 2017-02-15 成都六然医疗科技有限公司 Red complex probiotics composition for heart and cerebral vessels

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
刘锦秀，等: "乳酸菌在临床应用上的进展", 《食品与发酵科技》 *
牛天贵，等主编: "《现代食品免疫学》", 30 September 2010, 中国农业大学出版社 *
王凯旋: "基于乳酸菌转化的桑椹加工工艺优化及桑椹果片的研制", 《中国优秀硕士学位论文全文数据库 工程科技I辑》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109182225A (en) * 2018-10-30 2019-01-11 吉林省农业科学院 One plant of Pediococcus acidilactici and its application in antiatherosclerosis
CN109182225B (en) * 2018-10-30 2021-09-03 吉林省农业科学院 Pediococcus acidilactici and application thereof in resisting atherosclerosis
CN111500520A (en) * 2020-06-02 2020-08-07 光明乳业股份有限公司 Method for culturing lactobacillus plantarum
CN113249249A (en) * 2021-04-29 2021-08-13 南昌大学 Lactobacillus plantarum ZDY04 with effect of relieving atherosclerosis
WO2023237688A1 (en) * 2022-06-10 2023-12-14 Dsm Ip Assets B.V. Combinations comprising vitamin c and lactobacillus rhamnosus
WO2023237684A1 (en) * 2022-06-10 2023-12-14 Dsm Ip Assets B.V. Combinations comprising vitamin c and lactobacillus rhamnosus
WO2023237689A1 (en) * 2022-06-10 2023-12-14 Dsm Ip Assets B.V. Combinations comprising vitamin c and lactobacillus rhamnosus
WO2023237686A1 (en) * 2022-06-10 2023-12-14 Dsm Ip Assets B.V. Combinations comprising vitamin c and lactobacillus rhamnosus

Also Published As

Publication number Publication date
CN109125525B (en) 2021-06-15

Similar Documents

Publication Publication Date Title
CN109125525A (en) Composition of prevention and cure of cardiovascular disease and its preparation method and application
CN105167072B (en) A kind of production method of feature matrimony vine ferment and its product
CN105146614B (en) A kind of functional calcium fruit ferment, enzyme beverage and its production method
CN103190626B (en) Fruit and vegetable food for treating oral ulcer and preparation method of fruit and vegetable food
CN109666615A (en) A kind of probiotic composition and its application
CN109628358A (en) A kind of compound probiotic and its application
Albuquerque et al. Tropical fruit by-products water extracts of tropical fruit by-products as sources of soluble fibres and phenolic compounds with potential antioxidant, anti-inflammatory, and functional properties
CN106413724B (en) Lactobacillus rhamnosus RHT-3201 conjugated with polysaccharide polymer binder and uses thereof
CN107981324A (en) Turmeric fermented food and preparation method thereof
CN110468070A (en) Lactobacillus rhamnosus CCFM1060, its fermented food and bacterial preparation process
CN107692219A (en) A kind of hypoglycemic fruit zymotic fluid and preparation method thereof
CN105030950B (en) The probiotics and its preparation method and application for preventing and treating hyperlipidemia
KR101138783B1 (en) Process of fermentated tomato using lactic acid bacteria and its product
JP7007663B2 (en) Kuro-moji extract
EP3861866A1 (en) Composition comprising molokhia extract as active ingredient for improving gut microbiome or for alleviating, preventing, or treating intestinal inflammation, leaky gut syndrome, obesity, or metabolic disease
CN105802876B (en) A kind of composite probiotics ferment clover tender shoots powder preparation and its preparation method and application
KR102305931B1 (en) A food composition for improving circulation of blood and increasing functions of immune comprising natural extracts
CN113337435A (en) Probiotic composition and application thereof in food
KR102078509B1 (en) Preparing method of kimchi for improving lipid metabolism and preventing obesity
Kumar et al. Potato probiotics for human health
KR20120106218A (en) Manufacturing method of treated puffing and fermentation red ginseng concentrate
JP2012224551A (en) Composition for sustentation of bifidobacterium or lactobacillus
KR20160049732A (en) Method for preparing fermented bitter melon extract and a fu nctional food sauce and a functional fermented drink manufactured thereby
CN106983146A (en) Prepare the fermentation composition and preparation method of the plant enzyme with conditioning and enhancing human detoxification moistening face
Guergoletto et al. Nondairy probiotic and prebiotic beverages: applications, nutrients, benefits, and challenges

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant